Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics

Area of Science:

• Oncology
• Stem Cell Biology
• Drug Delivery

Background:

• Drug delivery to solid tumors is a major challenge in cancer treatment.
• Mesenchymal stem/stromal cells (MSCs) possess tumor-homing capabilities, making them potential vehicles for targeted cancer therapies.
• Preclinical studies demonstrate anti-tumor effects of MSC-delivered genes or drugs, with some clinical trials initiated.

Purpose of the Study:

• To review the use of MSCs as drug delivery vehicles in cancer therapy.
• To discuss MSC sources, heterogeneity, tumor-homing mechanisms, and administration routes.
• To summarize therapeutic applications and drug delivery mechanisms of MSC-based cancer treatments.

Main Methods:

• Review of preclinical and clinical studies on MSC-based cancer therapy.
• Analysis of MSC properties, including tumor homing and drug delivery mechanisms.
• Discussion of challenges and future directions for MSC-based cancer treatments.

Main Results:

• MSCs can be engineered to deliver therapeutic genes or anti-cancer drugs, showing significant preclinical anti-tumor activity.
• Clinical trials have shown limited therapeutic effects, highlighting the need for further optimization.
• Key factors for successful clinical outcomes include resolving MSC interdonor heterogeneity and enhancing tumor-homing and drug delivery efficiencies.

Conclusions:

• MSC-based cancer therapy holds potential but faces challenges in clinical translation.
• Addressing MSC heterogeneity and optimizing delivery mechanisms are crucial for improving therapeutic efficacy.
• Further research is needed to fully realize the potential of MSCs in targeted cancer drug delivery.